IMDZ SEC-arkiveringar - Immune Design Corp.- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

1437786

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immune Design Corp.

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

April 12, 2019	15-12B	IMDZ / Immune Design Corp. 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36561 IMMUNE DESIGN CORP. (Exact name of registrant as specified
April 2, 2019	S-8 POS	IMDZ / Immune Design Corp. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 2, 2019 Registration No.
April 2, 2019	S-8 POS	IMDZ / Immune Design Corp. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 2, 2019 Registration No.
April 2, 2019	S-8 POS	IMDZ / Immune Design Corp. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 2, 2019 Registration No.
April 2, 2019	S-8 POS	IMDZ / Immune Design Corp. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 2, 2019 Registration No.
April 2, 2019	S-8 POS	IMDZ / Immune Design Corp. S-8 POS S-8 POS As filed with the Securities and Exchange Commission on April 2, 2019 Registration No.
April 2, 2019	POS AM	IMDZ / Immune Design Corp. POS AM POS AM As filed with the Securities and Exchange Commission on April 2, 2019 Registration No.
April 2, 2019	EX-3.2	Amended and Restated Bylaws of Immune Design Corp. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF IMMUNE DESIGN CORP. ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors
April 2, 2019	EX-3.1	Amended and Restated Certificate of Incorporation of Immune Design Corp. EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNE DESIGN CORP. FIRST: The name of the corporation is Immune Design Corp. (hereinafter, the “corporation”). SECOND: The address of the corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, and the name of its register
April 2, 2019	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2019 Immune Design Corp. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (State or other jurisdiction of incorporation) (Commission F
April 2, 2019	SC 14D9/A	IMDZ / Immune Design Corp. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) IMMUNE DESIGN CORP. (Name of Subject Company) IMMUNE DESIGN CORP. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities
April 2, 2019	EX-99.(A)(5)(C)	Merck Completes Tender Offer to Acquire Immune Design Exhibit (a)(5)(C) Exhibit (a)(5)(c) News Release Media Contacts: Pamela Eisele (267) 305-3558 Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Merck Completes Tender Offer to Acquire Immune Design KENILWORTH, N.
April 2, 2019	SC TO-T/A	MRK / Merck & Co., Inc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Immune Design Corp. (Name of Subject Company — Issuer) CASCADE MERGER SUB INC. MERCK SHARP & DOHME CORP. (Names of Filing Persons — Offerors) Common Stock, par value $0.001 per share (Title o
March 28, 2019	10-K/A	Annual Report - FORM 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
March 26, 2019	SC TO-T/A	MRK / Merck & Co., Inc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Immune Design Corp. (Name of Subject Company — Issuer) CASCADE MERGER SUB INC. MERCK SHARP & DOHME CORP. (Names of Filing Persons — Offerors) Common Stock, par value $0.001 per share (Title o
March 22, 2019	SC 14D9/A	IMDZ / Immune Design Corp. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) IMMUNE DESIGN CORP. (Name of Subject Company) IMMUNE DESIGN CORP. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities
March 15, 2019	SC TO-T/A	MRK / Merck & Co., Inc. SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Immune Design Corp. (Name of Subject Company — Issuer) CASCADE MERGER SUB INC. MERCK SHARP & DOHME CORP. (Names of Filing Persons — Offerors) Common Stock, par value $0.001 per share (Title o
March 15, 2019	SC 14D9/A	IMDZ / Immune Design Corp. SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) IMMUNE DESIGN CORP. (Name of Subject Company) IMMUNE DESIGN CORP. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities
March 13, 2019	10-K	Annual Report - FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36561 IMMUNE
March 11, 2019	SC 13G/A	IMDZ / Immune Design Corp. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Immune Design Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L103 (CUSIP Number) February 28, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
March 5, 2019	EX-99.(E)(15)	Retention Bonus Payback Agreement, dated August 13, 2018, by and between Immune Design Corp. and Sergey Yurasov, M.D., Ph.D. (incorporated herein by reference to Exhibit 99(E)(15) to the Company’s Recommendation Statement on Schedule 14D-9 (File No. 005-88256), as filed with the SEC on March 5, 2019). EX-99.(e)(15) Exhibit (e)(15) August 13, 2018 Sergey Yurasov, M.D. 226 Twin Peaks Blvd. San Francisco, CA 94114 Re: Retention Program Dear Sergey, In recognition of your contributions to date and the important future objectives of Immune Design Corp. (the “Company”), the Company is offering you eligibility for a retention bonus on the terms described below. Retention Payment If you sign this lette
March 5, 2019	EX-99.(E)(17)	Retention Bonus Payback Agreement, dated November 7, 2018, by and between Immune Design Corp. and Stephen Brady (incorporated herein by reference to Exhibit 99(E)(17) to the Company’s Recommendation Statement on Schedule 14D-9 (File No. 005-88256), as filed with the SEC on March 5, 2019). EX-99.(e)(17) Exhibit (e)(17) RETENTION BONUS PAYBACK AGREEMENT Immune Design Corp. (the “Company”) recognizes the importance of your continued contributions to our efforts and, as of November 7, 2018, is offering you a retention bonus of two hundred thousand dollars ($200,000) (the “Retention Bonus”), subject to the terms and conditions outlined below. Your receipt of this Retention Bonus is expr
March 5, 2019	EX-99.(E)(16)	Retention Bonus Payback Agreement, dated November 7, 2018, by and between Immune Design Corp. and Jan ter Meulen, M.D. (incorporated herein by reference to Exhibit 99(E)(16) to the Company’s Recommendation Statement on Schedule 14D-9 (File No. 005-88256), as filed with the SEC on March 5, 2019). EX-99.(e)(16) Exhibit (e)(16) RETENTION BONUS PAYBACK AGREEMENT Immune Design Corp. (the “Company”) recognizes the importance of your continued contributions to our efforts and, as of November 7, 2018, is offering you a retention bonus of two hundred thousand dollars ($200,000) (the “Retention Bonus”), subject to the terms and conditions outlined below. Your receipt of this Retention Bonus is expr
March 5, 2019	SC 14D9	IMDZ / Immune Design Corp. SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 5, 2019	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL to Tender Shares of Common Stock Immune Design Corp. Pursuant to the Offer to Purchase dated March 5, 2019 Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of Immune Design Corp. Pursuant to the Offer to Purchase dated March 5, 2019 by Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT ONE MINUTE FOLLOWING 11:59PM, EASTERN TIME, ON APRIL 1, 2019, UNLESS THE OFFER IS EXTENDED OR TERMINATED. THIS
March 5, 2019	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Common Stock Immune Design Corp. $5.85 Net Per Share Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. and Merck & Co., Inc. EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Immune Design Corp. at $5.85 Net Per Share by Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. and Merck & Co., Inc. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT ONE MINUTE FOLLOWING 11:59 PM, EASTERN TIME, ON APRIL 1, 2019, UNLESS THE OFFER IS EXTENDE
March 5, 2019	SC TO-T	MRK / Merck & Co., Inc. SC TO-T SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Immune Design Corp. (Name of Subject Company — Issuer) CASCADE MERGER SUB INC. MERCK SHARP & DOHME CORP. (Names of Filing Persons — Offerors) Common Stock, par value $0.001 per share (Title of Class of Securitie
March 5, 2019	EX-99.(A)(1)(D)	Offer to Purchase for Cash All Outstanding Shares of Common Stock Immune Design Corp. $5.85 Net Per Share Pursuant to the Offer to Purchase dated March 5, 2019 Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Immune Design Corp. at $5.85 Net Per Share Pursuant to the Offer to Purchase dated March 5, 2019 by Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT ONE MINUTE FOLLOWING 11:59 PM, EASTERN TIME, ON APRIL 1, 2019, UNLESS THE OF
March 5, 2019	EX-99.(A)(1)(E)	Offer to Purchase for Cash All Outstanding Shares of Common Stock Immune Design Corp. $5.85 Net Per Share Pursuant to the Offer to Purchase dated March 5, 2019 Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Immune Design Corp. at $5.85 Net Per Share Pursuant to the Offer to Purchase dated March 5, 2019 by Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT ONE MINUTE FOLLOWING 11:59 PM, EASTERN TIME, ON APRIL 1, 2019, UNLESS THE OF
March 5, 2019	EX-99.(D)(2)	CONFIDENTIALITY AGREEMENT EX-99.(d)(2) Exhibit (d)(2) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of December 4, 2018, between IMMUNE DESIGN CORP., a Delaware corporation (the “Company”), and Merck Sharp & Dohme Corp., a New Jersey corporation (“Counterparty”). In order to facilitate the consideration and negotiation of a possible transaction between the Company and Count
March 5, 2019	EX-99.(A)(1)(F)	Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock Immune Design Corp. $5.85 Net Per Share Pursuant to the Offer to Purchase Dated March 5, 2019 Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase dated March 5, 2019 and the related letter of transmittal and any amendments or supplements thereto. The Offer is not being made to (nor will tenders be accepted from or on behalf o
March 5, 2019	EX-99.(A)(1)(C)	NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock Immune Design Corp. Pursuant to the Offer to Purchase dated March 5, 2019 Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. EX-99.(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Immune Design Corp. Pursuant to the Offer to Purchase dated March 5, 2019 by Cascade Merger Sub Inc. a wholly owned subsidiary of Merck Sharp & Dohme Corp. THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT ONE MINUTE FOLLOWING 11:59 PM, EASTERN TIME, ON APRIL 1, 2019, UNLESS THE OFFER IS EXTENDED OR TERMINA
March 5, 2019	EX-99.(A)(5)(B)	Merck Begins Tender Offer to Acquire Immune Design EX-99.(a)(5)(B) Exhibit (a)(5)(B) News Release FOR IMMEDIATE RELEASE Media Contacts: Pamela Eisele Investor Contacts: Peter Dannenbaum (267) 305-3558 (908) 740-1037 Courtney Ronaldo (908) 740-6132 Merck Begins Tender Offer to Acquire Immune Design KENILWORTH, N.J., March 5, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cas
March 5, 2019	EX-99.(D)(1)	AGREEMENT AND PLAN OF MERGER IMMUNE DESIGN CORP., a Delaware corporation; MERCK SHARP & DOHME CORP., a New Jersey corporation; and CASCADE MERGER SUB INC., a Delaware corporation Dated as of February 20, 2019 EX-99.(d)(1) Exhibit (d)(1) AGREEMENT AND PLAN OF MERGER among: IMMUNE DESIGN CORP., a Delaware corporation; MERCK SHARP & DOHME CORP., a New Jersey corporation; and CASCADE MERGER SUB INC., a Delaware corporation Dated as of February 20, 2019 TABLE OF CONTENTS Page SECTION 1. THE OFFER 2 1.1 The Offer. 2 1.2 Company Actions. 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into the Compa
February 28, 2019	SC 13D/A	IMDZ / Immune Design Corp. / Versant Venture Capital III, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* IMMUNE DESIGN CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L103 (CUSIP Number) Versant Venture Cap
February 25, 2019	SC 13G/A	IMDZ / Immune Design Corp. / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L103 (CUSIP Number) February 21, 2
February 21, 2019	EX-99.(II)	Dear [_____], EX-99.(ii) Exhibit (ii) Dear [], We are pleased to inform you that today we announced that Immune Design and Merck have signed an agreement pursuant to which Merck, through a subsidiary, will acquire Immune Design. I have attached the press release for your information. Upon successful completion of the acquisition, we believe Immune Designs technologies will be positioned for long-term success w
February 21, 2019	SC14D9C	IMDZ / Immune Design Corp. SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 IMMUNE DESIGN CORP. (Name of Subject Company) IMMUNE DESIGN CORP. (Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 45252L103 (CUSIP N
February 21, 2019	EX-99.(I)	Safe Harbor Forward-Looking Statements This presentation may contain certain forward-looking statements regarding Immune Design, including without limitation with respect to its business, the proposed tender offer and merger, the expected timetable f EX-99.(i) Project Ibiza: Employee All-Hands Exhibit (i) Safe Harbor Notice to Investors/Important Additional Information Filed with the U.S. Securities and Exchange Commission This presentation is not a recommendation, an offer to purchase or a solicitation of an offer to sell shares of Immune Design Corp. (“Immune Design”) stock. Cascade Merger Sub Inc. (“Purchaser”) has not commenced the tender
February 21, 2019	EX-2.1	Agreement and Plan of Merger, dated February 20, 2019, by and among Immune Design Corp., Merck Sharp & Dohme Corp. and Cascade Merger Sub Inc. (incorporated herein by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K (File No. 001-36561), as filed with the SEC on February 20, 2019). EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: IMMUNE DESIGN CORP., a Delaware corporation; MERCK SHARP & DOHME CORP., a New Jersey corporation; and CASCADE MERGER SUB INC., a Delaware corporation Dated as of February 20, 2019 TABLE OF CONTENTS Page SECTION 1. THE OFFER 2 1.1 The Offer. 2 1.2 Company Actions. 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into the Company 5 2.2
February 21, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d689051d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 Immune Design Corp. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (State or other jurisdiction of inc
February 21, 2019	EX-99.1	Merck to Acquire Immune Design Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer EX-99.1 Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Media Contact: Pamela Eisele Merck Investor Contacts: Peter Dannenbaum (267) 305-3558 (908) 740-1037 Courtney Ronaldo (908) 740-6132 Immune Design Media Contact: Julie Rathbun (206) 769-9219 Immune Design Investor Contact: Sylvia Wheeler (650) 392-8318 Merck to Acquire Immune Design Acquisition Bolsters Capabilities in Vaccine Developme
February 21, 2019	EX-2.1	Agreement and Plan of Merger, dated as of February 20, 2019, by and among Immune Design Corp., Merck Sharp & Dohme Corp. and Cascade Merger Sub Inc. EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: IMMUNE DESIGN CORP., a Delaware corporation; MERCK SHARP & DOHME CORP., a New Jersey corporation; and CASCADE MERGER SUB INC., a Delaware corporation Dated as of February 20, 2019 TABLE OF CONTENTS Page SECTION 1. THE OFFER 2 1.1 The Offer. 2 1.2 Company Actions. 4 SECTION 2. MERGER TRANSACTION 5 2.1 Merger of Purchaser into the Company 5 2.2
February 21, 2019	SC TO-C	IMDZ / Immune Design Corp. 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 Immune Design Corp. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (State or other jurisdiction of incorporation) (Commissi
February 21, 2019	EX-99.1	Joint Press Release of Immune Design Corp. and Merck & Co., Inc. dated February 21, 2019. EX-99.1 Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Media Contact: Pamela Eisele Merck Investor Contacts: Peter Dannenbaum (267) 305-3558 (908) 740-1037 Courtney Ronaldo (908) 740-6132 Immune Design Media Contact: Julie Rathbun (206) 769-9219 Immune Design Investor Contact: Sylvia Wheeler (650) 392-8318 Merck to Acquire Immune Design Acquisition Bolsters Capabilities in Vaccine Developme
February 21, 2019	EX-99.1	Merck to Acquire Immune Design Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer EX-99.1 Exhibit 99.1 News Release FOR IMMEDIATE RELEASE Merck Media Contact: Pamela Eisele (267) 305-3558 Merck Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Immune Design Media Contact: Julie Rathbun (206) 769-9219 Immune Design Investor Contact: Sylvia Wheeler (650) 392-8318 Merck to Acquire Immune Design Acquisition Bolsters Capabilities in Vaccine Developme
February 21, 2019	SC TO-C	MRK / Merck & Co., Inc. SC TO-C SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Immune Design Corp. (Name of Subject Company — Issuer) CASCADE MERGER SUB INC. MERCK SHARP & DOHME CORP. (Names of Filing Persons — Offerors) Common Stock, par value $0.001 per share (Title of Class of Securitie
February 19, 2019	SC 13D/A	IMDZ / Immune Design Corp. / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A 1 d670438dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L 103 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158
February 19, 2019	EX-99.A	Joint Filing Statement EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D/A is filed on behalf of each of us. Dated: February 19, 2019 THE COLUMN GROUP, LP THE COLUMN GROUP GP, LP By: The Column Group GP, LP By: /s/ Peter Svennilson By: /s/ Peter Svennilson Name: Peter Svennilson Name: Peter Svennilson Title: Managing Partner Title: Managing Partner
February 14, 2019	SC 13G/A	IMDZ / Immune Design Corp. / BROOKSIDE CAPITAL MANAGEMENT LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immune Design Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
February 14, 2019	SC 13G/A	IMDZ / Immune Design Corp. / Biotechnology Value Fund L P - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2
January 28, 2019	SC 13G/A	IMDZ / Immune Design Corp. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 immu18a1.htm CUSIP NO. 45252L103 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IMMUNE DESIGN CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of t
January 10, 2019	SC 13G/A	IMDZ / Immune Design Corp. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Immune Design Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 8, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2019 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fil
December 7, 2018	8-K	Termination of a Material Definitive Agreement 8-K 1 immuneform8kdec18.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdic
November 13, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fi
November 6, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fi
November 6, 2018	EX-99.1	Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update – Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif.
November 6, 2018	10-Q	IMDZ / Immune Design Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
October 17, 2018	SC 13G/A	IMDZ / Immune Design Corp. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga10742200310162018.htm AMENDMENT NO. 1 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par v
October 11, 2018	EX-99.1	Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305 Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305 • G100 development to accelerate in follicular lymphoma and beyond • CMB305 to be deprioritized to support focus on G100 • Cash runway extended into 2021 • Conference call at 2:00 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif.
October 11, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fi
September 4, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 immuneform8kres.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdictio
August 1, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission File
August 1, 2018	EX-99.1	Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update – G100 advancing to late-stage development following FDA feedback – Conference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug.
August 1, 2018	10-Q	IMDZ / Immune Design Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
July 27, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission File
July 18, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission File
July 18, 2018	SC TO-I/A	IMDZ / Immune Design Corp. SCHEDULE TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 2) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IMMUNE DESIGN CORP. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 45252L103 (CUSIP Number
June 26, 2018	SC TO-I/A	IMDZ / Immune Design Corp. SCHEDULE TO-I/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IMMUNE DESIGN CORP. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 45252L103 (CUSIP Number
June 18, 2018	EX-99.(A)(1)(J)	Stock Option Exchange Program Presentation exjemployeepresentation OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS Exchange Offer – Relevant Documents and Dates • Relevant Documents – filed with SEC and provided by Email − Offer to Exchange Eligible Options for New Options • Summary of Terms • Questions and Answers • Offering Memorandum − Election Forms − Notice of Withdrawal of Election Forms • Relevant Dates − Tender Offer commenced on Monday, June 18, 2018 − Expiration Time is 6:00pm, Tuesday, July 17, 2018, unless extended − New Options will be granted promptly following the Expiration Time • Election Forms and Communications − We have set up a designated email account for the Exchange Offer − All Election Forms must go to option.
June 18, 2018	EX-99.(A)(1)(D)	Notice of Withdrawal of Election Form Exhibit (a)(1)(D) INSTRUCTIONS TO NOTICE OF WITHDRAWAL OF ELECTION FORM If you previously elected to accept the offer by Immune Design Corp.
June 18, 2018	EX-99.(A)(1)(C)	Election Form EX-99.(A)(1)(C) 4 exa1c-electionform.htm EXHIBIT 99.(A)(1)(C) Confidential Exhibit (a)(1)(C) IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE, WASHINGTON 98102 OPTION EXCHANGE – ELECTION FORM THIS OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 6:00 P.M., PACIFIC TIME, ON TUESDAY, JULY 17, 2018, UNLESS EXTENDED Before completing and signing this Election Form, we encourage you to read the d
June 18, 2018	EX-99.(A)(1)(H)	Form of Confirmation Letter to Eligible Holders Participating in the Exchange Offer Exhibit (a)(1)(H) FORM OF CONFIRMATION LETTER TO ELIGIBLE EMPLOYEES PARTICIPATING IN THE EXCHANGE OFFER From: Immune Design Corp.
June 18, 2018	EX-99.(A)(1)(E)	Form of Email Confirming Receipt of Election Form Exhibit (a)(1)(E) FORM OF COMMUNICATION TO ELIGIBLE HOLDERS CONFIRMING RECEIPT OF ELECTION FORM From: Immune Design Corp.
June 18, 2018	EX-99.(A)(1)(B)	Form of Announcement Email Exhibit (a)(1)(B) Subject: Immune Design - Offer to Exchange Eligible Options for New Options To: All Eligible Holders Date: June 18, 2018 We are pleased to announce that Immune Design Corp.
June 18, 2018	EX-99.(A)(1)(A)	Offer to Exchange Eligible Options for New Options, dated June 18, 2018 Exhibit (a)(1)(A) IMMUNE DESIGN CORP. 1616 EASTLAKE AVE. E., SUITE 310 SEATTLE, WASHINGTON 98102 OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS JUNE 18, 2018 IMMUNE DESIGN CORP. SUMMARY TERM SHEET — OVERVIEW OFFER TO EXCHANGE ELIGIBLE OPTIONS FOR NEW OPTIONS This offer and withdrawal rights will expire at 6:00 p.m., Pacific Time, on Tuesday, July 17, 2018, unless extended (or at any time after
June 18, 2018	EX-99.(A)(1)(F)	Form of Email Confirming Receipt of Notice of Withdrawal of Election Form Exhibit (a)(1)(F) FORM OF COMMUNICATION TO ELIGIBLE HOLDERS CONFIRMING RECEIPT OF NOTICE OF WITHDRAWAL OF ELECTION FORM From: Immune Design Corp.
June 18, 2018	SC TO-I	IMDZ / Immune Design Corp. SCHEDULE TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IMMUNE DESIGN CORP. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 45252L103 (CUSIP Number of Clas
June 18, 2018	EX-99.(A)(1)(I)	Form of Expiration Notice Email EX-99.(A)(1)(I) 10 exa1i-expirationnotice.htm EXHIBIT 99.(A)(1)(I) Exhibit (a)(1)(I) NOTICE OF EXPIRATION OF EXCHANGE OFFER From: Immune Design Corp. Re: Expiration of the Exchange Offer The Offer to Exchange Eligible Options for New Options, dated June 18, 2018 (the “Exchange Offer”), has expired, and no additional Election Forms may be submitted. If you are an Eligible Employee and delivered a p
June 18, 2018	EX-99.(A)(1)(G)	Form of Reminder Email Exhibit (a)(1)(G) FORM OF REMINDER TO ELIGIBLE EMPLOYEES REGARDING THE EXPIRATION OF THE EXCHANGE OFFER From: Immune Design Corp.
June 15, 2018	8-K	Submission of Matters to a Vote of Security Holders 8-K 1 form8k-meeting18.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction
May 3, 2018	10-Q	IMDZ / Immune Design Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
May 2, 2018	EX-99.1	Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update • The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3 • The 20ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10ug dose • Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif.
May 2, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 immuneform8k1q18.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction o
April 26, 2018	SC TO-C	IMDZ / Immune Design Corp. SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IMMUNE DESIGN CORP. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 45252L103 (CUSIP Number of Clas
April 26, 2018	DEF 14A	Notice of Annual Meeting of Stockholders and Definitive Proxy Statement for 2018 Annual Meeting of Stockholders of Immune Design Corp. (incorporated by reference to the Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2018) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a‑101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the
April 10, 2018	SC TO-C	IMDZ / Immune Design Corp. SC TO-C SC TO-C 1 scheduleto.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 13e-4) Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 IMMUNE DESIGN CORP. (Name of Subject Company (Issuer) and Filing Person (Offeror)) Options to Purchase Common Stock, Par Value $0.001 Per Share (Title of Class of Securities
April 10, 2018	PRE 14A	Notice of Annual Meeting of Stockholders and Preliminary Proxy Statement for 2018 Annual Meeting of Stockholders of Immune Design Corp. (incorporated by reference to the Preliminary Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 10, 2018) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a‑101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: ý Preliminary Proxy Statement o Confidential, for Use of the
March 14, 2018	S-8	IMDZ / Immune Design Corp. FORM S-8 As filed with the Securities and Exchange Commission on March 14, 2018 Registration No.
March 14, 2018	8-K	IMDZ / Immune Design Corp. FORM 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission File
March 14, 2018	EX-99.1	Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update – New positive clinical and translational data for both lead agents – Strong balance sheet with 2017 year-end cash and equivalents of $144.
March 14, 2018	10-K	IMDZ / Immune Design Corp. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36561 IMMUNE
February 14, 2018	SC 13G/A	IMDZ / Immune Design Corp. / ProQuest Investments IV, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
February 14, 2018	SC 13G/A	IMDZ / Immune Design Corp. / BROOKSIDE CAPITAL MANAGEMENT LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immune Design Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
February 9, 2018	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 9, 2018 with respect to the shares of Common Stock of Immune Design Corp., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the
February 9, 2018	SC 13G	IMDZ / Immune Design Corp. / Biotechnology Value Fund L P - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L103 (CUSIP Number) January 30, 201
February 9, 2018	SC 13G/A	IMDZ / Immune Design Corp. / Biotechnology Value Fund L P - AMENDMENT NO. 2 TO THE SCHEDULE 13G Passive Investment SC 13G/A 1 sc13ga207422imm02092018.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par v
February 8, 2018	SC 13G/A	IMDZ / Immune Design Corp. / VICTORY CAPITAL MANAGEMENT INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 2 )* Immune Design Corp (Name of Issuer) Common Stock (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
February 7, 2018	SC 13G/A	IMDZ / Immune Design Corp. / Topspin Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tv483100sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropr
February 7, 2018	SC 13G	IMDZ / Immune Design Corp. / FRANKLIN RESOURCES INC Passive Investment CUSIP NO. 45252L103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immune Design Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the
January 9, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2018 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commi
December 13, 2017	EX-99.1	Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients Exhibit Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients ? 39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 high patient population receiving G100+pembrolizumab (potential predictive biomarker) ? Responses occur in both recurrent/refractory and treatment-na?ve patient populations ? Data presented at ASH 2017 ? Conference call Monday, December 11 at 8:00 a.
December 13, 2017	8-K	IMDZ / Immune Design Corp. FORM 8-K (Current Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Com
November 6, 2017	SC 13G	IMDZ / Immune Design Corp. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Immune Design Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L103 (CUSIP Number) October 25, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p
November 1, 2017	EX-99.1	Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today Exhibit Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.
November 1, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fi
November 1, 2017	10-Q	IMDZ / Immune Design Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
October 30, 2017	EX-99.A	Joint Filing Statement EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D/A is filed on behalf of each of us. Dated as October 30, 2017 THE COLUMN GROUP, LP THE COLUMN GROUP GP, LP By: The Column Group GP, LP By: /s/ Peter Svennilson By: /s/ Peter Svennilson Name: Peter Svennilson Name: Peter Svennilson Title: Managing Partner Title: Managing Partner
October 30, 2017	SC 13D/A	IMDZ / Immune Design Corp. / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L 103 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name, Address
October 25, 2017	EX-99.2	Immune Design Prices $80.0 Million Public Offering of Common Stock EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Immune Design Prices $80.0 Million Public Offering of Common Stock SEATTLE and SOUTH SAN FRANCISCO, October 24, 2017 ? Immune Design Corp. (Nasdaq: IMDZ) announced today the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price to the public of $4.10 per share. All of the shares of common stock are being offered by
October 25, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d484948d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2017 Immune Design Corp. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (State or other jurisdiction of
October 25, 2017	EX-1.1	Underwriting Agreement, dated October 24, 2017, between the Company and the Underwriters named therein. EX-1.1 Exhibit 1.1 19,500,000 Shares of Common Stock Immune Design Corp. UNDERWRITING AGREEMENT October 24, 2017 LEERINK PARTNERS LLC COWEN AND COMPANY, LLC RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters c/o LEERINK PARTNERS LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 c/o RBC CAPITA
October 25, 2017	EX-99.1	Immune Design Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 Immune Design Announces Proposed Public Offering of Common Stock SEATTLE and SOUTH SAN FRANCISCO, October 23, 2017? Immune Design Corp. (Nasdaq: IMDZ) announced today that it plans to offer and sell up to 16,000,000 shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Design. The offering is subject
October 25, 2017	424B5	19,500,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-206324 PROSPECTUS SUPPLEMENT (to Prospectus dated December 29, 2015) 19,500,000 Shares Common Stock We are offering 19,500,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol ?IMDZ.? On October 24, 2017, the last reported sale price of our common stock on The NASDAQ Glo
October 23, 2017	EX-99.1	FORWARD-LOOKING STATEMENTS EX-99.1 Exhibit 99.1 As used in this Exhibit 99.1, ?Immune Design,? ?Immune Design Corp.,? the ?Company,? ?we,? ?us? and ?our? refer to Immune Design Corp., a Delaware corporation. ZVex and GLAAS are U.S. registered trademarks of Immune Design Corp. All other trademarks, service marks and trade names included in this Exhibit 99.1 are the property of their respective owners. FORWARD-LOOKING STATEME
October 23, 2017	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2016 IMMUNE DESIGN CORP. (Exact name of Registrant as Specified in its Charter) Delaware 001-36561 26-2007174 (State or Other Jurisdiction of Incorporation) (Comm
October 23, 2017	424B5	SUBJECT TO COMPLETION, DATED October 23, 2017 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-206324 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospe
October 16, 2017	EX-99.1	Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial for CMB305 in Synovial Sarcoma Patients EX-99.1 2 exhibit991oct17pres.htm EXHIBIT 99.1 Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial for CMB305 in Synovial Sarcoma Patients • CMB305 Monotherapy vs. Placebo in the Maintenance Setting • PFS Analysis for Potential Full Approval as Early as 24 Months After Study Start • Conference Call and Webcast Tomorrow at 5:30am PT/8:30am ET SEATTLE and SOUTH SAN FRANCISCO, Oct
October 16, 2017	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Comm
September 8, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission F
September 8, 2017	EX-99.1	New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response Exhibit New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response ? Phase 2 Interim Analysis Data Presented at ESMO 2017 Congress SEATTLE and SOUTH SAN FRANCISCO, Calif.
August 30, 2017	EX-99.1	Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress EX-99.1 2 exhibit991esmo2017.htm EXHIBIT 99.1 Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress • Interim data analysis shows greater clinical benefit and immune response with CMB305+atezolizumab than with atezolizumab alone SEATTLE and SOUTH SAN FRANCISCO, August 30, 2017 - Immune Design (Nasdaq: IMDZ), a clinical-stage
August 30, 2017	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commi
August 2, 2017	EX-99.1	Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today Exhibit Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.
August 2, 2017	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commis
August 2, 2017	10-Q	IMDZ / Immune Design Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
July 3, 2017	EX-1.1	IMMUNE DESIGN CORP. Common Stock (par value $0.001 per share) SALES AGREEMENT EX-1.1 Exhibit 1.1 IMMUNE DESIGN CORP. Common Stock (par value $0.001 per share) SALES AGREEMENT July 3, 2017 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Immune Design Corp., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees
July 3, 2017	EX-99.1	FORWARD-LOOKING STATEMENTS EX-99.1 Exhibit 99.1 As used in this Exhibit 99.1, ?Immune Design,? ?Immune Design Corp.,? the ?Company,? ?we,? ?us,? ?our? and similar references refer to Immune Design Corp., a Delaware corporation. ZVex and GLAAS are registered trademarks of Immune Design Corp. The Immune Design logo is the unregistered trademark of Immune Design Corp. All other registered marks, trademarks and trade names incl
July 3, 2017	8-K	Immune Design 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fi
July 3, 2017	424B5	Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-206324 PROSPECTUS SUPPLEMENT (to Prospectus dated December 29, 2015) $50,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance w
June 15, 2017	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commiss
May 17, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission File N
May 17, 2017	EX-99.1	Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 2:00 p.m. PT today Exhibit Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 2:00 p.
May 17, 2017	EX-99.2	New Clinical and Biomarker Data Validate Immune Design’s Lead Programs and Discovery Platforms Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017 Exhibit New Clinical and Biomarker Data Validate Immune Design?s Lead Programs and Discovery Platforms Data from CMB305 and G100 to be Presented at ASCO Annual Meeting in June 2017 SEATTLE and SOUTH SAN FRANCISCO, May 17, 2017 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, reported new clinical and biomarker data today from CMB305 and G100 monotherapy studies.
May 10, 2017	S-8	Immune Design FORM S-8 Document As filed with the Securities and Exchange Commission on May 10, 2017 Registration No.
May 4, 2017	10-Q	Immune Design FORM 10-Q (Quarterly Report) 10-Q 1 imdz331201710-q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2017 or ¨ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File
May 3, 2017	10-Q/A	Immune Design 10-Q/A (Quarterly Report) 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No.
May 3, 2017	EX-10.1	License Agreement, dated August 6, 2014, by and between Immune Design Corp. and Aventis Inc. (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q/A (File No. 001-36561), as filed with the SEC on May 3, 2017). EX-10.1 Exhibit 10.1 CONFIDENTIAL ? EXECUTION COPY *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. LICENSE AGREEMENT BETWEEN IMMUNE DESIGN CORP. AND AVENTIS INC. DATED AS OF A
April 26, 2017	DEF 14A	Immune Design DEF 14A IMDZ - 2017 Proxy Statement Combined Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 7, 2017	10-K	Immune Design FORM 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36561 IMMUNE
March 7, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission File
March 7, 2017	EX-99.1	Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update Company to hold conference call at 1:30 pm Pacific today Exhibit Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update Company to hold conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif.
March 3, 2017	8-K/A	Immune Design FORM 8-K/A (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of
March 3, 2017	EX-10.1	Confidential Settlement Agreement, dated October 17, 2016, by and between Immune Design Corp. and TheraVectys SA (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A (File No. 001-36561), as filed with the SEC on March 3, 2017). EX-10.1 2 tvsdoc1.htm EXHIBIT 10.1 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Exhibit 10.1 CONFIDENTIAL SETTLEMENT AGREEMENT THIS CONFIDENTIAL SETTLEMENT AGREEMENT (this “Agreement”), which shall be
March 3, 2017	EX-10.2	License Agreement, dated October 17, 2016, by and between Immune Design Corp. and TheraVectys SA (incorporated herein by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K/A (File No. 001-36561), as filed with the SEC on March 3, 2017). Exhibit [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
February 14, 2017	SC 13G/A	IMDZ / Immune Design Corp. / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDUE 13G Passive Investment SC 13G/A 1 sc13ga10742203302142017.htm AMENDMENT NO. 1 TO THE SCHEDUE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Immune Design Corp. (Name of Issuer) Common stock, $0.001 par va
February 10, 2017	SC 13G/A	IMDZ / Immune Design Corp. / VICTORY CAPITAL MANAGEMENT INC - IMMUNE DESIGN 13G-A 123116 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. 1 )* Immune Design Corp (Name of Issuer) Common Stock (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
January 10, 2017	EX-10.1	Form of Restricted Stock Unit Agreement under the Immune Design Corp. 2014 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-36561), as filed with the SEC on January 10, 2017). Exhibit IMMUNE DESIGN CORP. 2014 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Immune Design Corp., a Delaware corporation (the ? Company ?), hereby grants restricted stock units relating to the shares of the Company?s common stock, par value $0.001 per share (the ? Common Stock ?), to the Grantee named below. Additional terms and conditions of the grant are set forth on this cover sheet
January 10, 2017	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2017 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commi
December 16, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Com
November 14, 2016	EX-99.1	Joint Filing Agreement Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated November 14, 2016 with respect to the shares of Common Stock of Immune Design Corp., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under th
November 14, 2016	SC 13G	IMDZ / Immune Design Corp. / Biotechnology Value Fund L P - SCHEDULE 13G Passive Investment SC 13G 1 sc13g0742201011142016.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Immune Design Corp. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Secu
November 9, 2016	EX-10.1	LICENSE AGREEMENT BETWEEN IMMUNE DESIGN CORP. AND AVENTIS INC. DATED AS OF AUGUST 6, 2014 Exhibit *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
November 9, 2016	10-Q	Immune Design FORM 10-Q (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
November 9, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Comm
November 9, 2016	EX-99.1	Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today Exhibit Immune Design Reports Third Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.
November 9, 2016	EX-10.2	Employment Agreement, dated September 30, 2016, by and between Immune Design Corp. and Sergey Yurasov, M.D., Ph.D. (incorporated herein by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-36561), as filed with the SEC on November 9, 2016). EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of September 30, 2016 (the “Effective Date”), between SERGEY YURASOV, M.
October 21, 2016	8-K	Entry into a Material Definitive Agreement, Other Events Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Comm
September 30, 2016	SC 13G/A	IMDZ / Immune Design Corp. / Topspin Fund, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
September 23, 2016	SC 13G/A	IMDZ / Immune Design Corp. / RS INVESTMENT MANAGEMENT CO LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immune Design Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45252L103 (CUSIP Number) July 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
September 23, 2016	SC 13G	IMDZ / Immune Design Corp. / VICTORY CAPITAL MANAGEMENT INC - IMMUNE DESIGN 13G 073116 Passive Investment SC 13G 1 immunedesign13g073116.htm IMMUNE DESIGN 13G 073116 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ( Amendment No. )* Immune Design Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45252L103 (CUSIP Number) Victory Capital Management Inc., 4900 Tiedeman Rd, 4th Floor, Brooklyn, OH 44144 (
September 22, 2016	SC 13D/A	IMDZ / Immune Design Corp. / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L 103 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name, Address
September 22, 2016	EX-99.A	Joint Filing Statement EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D/A is filed on behalf of each of us. Dated as September 22, 2016 THE COLUMN GROUP, LP THE COLUMN GROUP GP, LP By: The Column Group GP, LP By: /s/ Peter Svennilson By: /s/ Peter Svennilson Name: Peter Svennilson Name: Peter Svennilson Title: Managing Partner Title: Managing Partn
September 16, 2016	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2016 Immune Design Corp. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (State or other jurisdiction of incorporation) (Commission
September 16, 2016	EX-99.1	Immune Design Announces Proposed Public Offering of Common Stock EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Immune Design Announces Proposed Public Offering of Common Stock SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) ? Immune Design Corp. (Nasdaq: IMDZ) announced today that it plans to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Des
September 16, 2016	EX-99.2	Immune Design Prices Public Offering of Common Stock EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE Immune Design Prices Public Offering of Common Stock SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) ? Immune Design Corp. (Nasdaq: IMDZ) announced today the pricing of an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $6.25 per share. All of the shares of common stock are being of
September 16, 2016	EX-1.1	4,800,000 Shares of Common Stock Immune Design Corp. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 Execution Version 4,800,000 Shares of Common Stock Immune Design Corp. UNDERWRITING AGREEMENT September 15, 2016 JEFFERIES LLC LEERINK PARTNERS LLC WELLS FARGO SECURITIES, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC One Federal Street, 37th Floor Boston, Massachusetts 02110 c/o WELLS FA
September 16, 2016	424B5	4,800,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-206324 PROSPECTUS SUPPLEMENT (to Prospectus dated December 29, 2015) 4,800,000 Shares Common Stock We are offering 4,800,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol IMDZ. On September 13, 2016, the last reported sale price of our common stock on The NASDAQ Glo
September 14, 2016	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d261314d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2016 IMMUNE DESIGN CORP. (Exact name of Registrant as Specified in its Charter) Delaware 001-36561 26-2007174 (State or Other Jurisdiction
September 14, 2016	EX-99.1	FORWARD-LOOKING STATEMENTS EX-99.1 Exhibit 99.1 As used in this Exhibit 99.1, Immune Design, Immune Design Corp., the Company, we, us and our refer to Immune Design Corp., a Delaware corporation. ZVex is a U.S. registered trademark and GLAAS is an unregistered U.S. trademark of Immune Design Corp. All other trademarks, service marks and trade names included in this Exhibit 99.1 are the property of their respecti
September 14, 2016	424B5	Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-206324 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospe
August 9, 2016	10-Q	Immune Design 10-Q (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
August 9, 2016	EX-10.1	Lease Agreement, dated January 1, 2016, by and between Immune Design Corp. and ARE-Eastlake Avenue No. 3, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-36561), as filed with the SEC on August 9, 2016). Exhibit LEASE AGREEMENT THIS LEASE AGREEMENT (this ? Lease ?) is made this 1st day of January, 2016, between ARE-EASTLAKE AVENUE NO.
August 9, 2016	EX-10.1	Lease Agreement, dated January 1, 2016, by and between Immune Design Corp. and ARE-Eastlake Avenue No. 3, LLC (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-36561), as filed with the SEC on August 9, 2016). Exhibit LEASE AGREEMENT THIS LEASE AGREEMENT (this ? Lease ?) is made this 1st day of January, 2016, between ARE-EASTLAKE AVENUE NO.
August 9, 2016	10-Q	Immune Design 10-Q (Quarterly Report) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
August 9, 2016	EX-99.1	Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today Exhibit Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.
August 9, 2016	EX-99.1	Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today Exhibit Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.
August 9, 2016	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commis
August 9, 2016	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commis
August 9, 2016	EX-10.2	SEPARATION DATE RELEASE (To be signed and returned to the Company on the Separation Date) June 28, 2016 Richard T. Kenney, M.D. [Address] [Address] Dear Dr. Kenney: As we have discussed, in connection with changes in our clinical organization, your job title with Immune Design Corp. (the “Company”) will be changed to Principal Medical Advisor. To retain your employment during this transition, the Company is offering you this transition agreement (the “Agreement”) to specify and confirm
July 1, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commiss
June 21, 2016	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commiss
June 21, 2016	EX-99.1	Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors Exhibit Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors SEATTLE and SOUTH SAN FRANCISCO, June 16, 2016 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Susan L. Kelley, M.D. to the Company?s Board of Directors. Dr. Kelley has more than 25 years? experience in oncology and immunology drug development. She
May 10, 2016	EX-10.1	IMMUNE DESIGN CORP. 2014 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT EX-10.1 2 amendedrsuagreement.htm EXHIBIT 10.1 IMMUNE DESIGN CORP. 2014 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Immune Design Corp., a Delaware corporation (the “Company”), hereby grants restricted stock units relating to the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), to the Grantee named below. Additional terms and conditions of the grant
May 10, 2016	10-Q	Immune Design FORM 10-Q (Quarterly Report) SEC Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
May 10, 2016	EX-99.1	Immune Design Reports First Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT Today EX-99.1 2 exhibit991earnings1q16.htm EXHIBIT 99.1 Immune Design Reports First Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT Today SEATTLE and SOUTH SAN FRANCISCO, May 10, 2016 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate review for the first quarter
May 10, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition SEC Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Comm
May 10, 2016	S-8	Immune Design FORM S-8 SEC Document As filed with the Securities and Exchange Commission on May 10, 2016 Registration No.
May 2, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission
April 26, 2016	DEF 14A	Immune Design DEF 14A DEF 14A 1 imdz2016proxystatementfinal.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a‑101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Prelimina
March 15, 2016	10-K	Immune Design FORM 10-K (Annual Report) 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 10, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission
March 10, 2016	EX-99.1	Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update Company to hold conference call at 1:30 pm Pacific today EX-99.1 2 exhibit991earnings4q.htm EXHIBIT 99.1 Immune Design Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update Company to hold conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., March 10, 2016 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corp
February 16, 2016	EX-10.1	Second Amended and Restated License Agreement, dated December 23, 2015, by and between Immune Design Corp. and the Infectious Disease Research Institute (incorporated herein by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A (File No. 001-36561), as filed with the SEC on February 16, 2016). EX-10.1 Exhibit 10.1 *** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Execution Copy SECOND AMENDED AND RESTATED LICENSE AGREEMENT This Second Amended and Restated License Agre
February 16, 2016	8-K/A	Financial Statements and Exhibits Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction
February 12, 2016	SC 13G	IMDZ / Immune Design Corp. / RS INVESTMENT MANAGEMENT CO LLC - IMMUNE DESIGN CORPORATION Passive Investment SC 13G 1 d134825dsc13g.htm IMMUNE DESIGN CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immune Design Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the approp
February 12, 2016	SC 13G/A	IMDZ / Immune Design Corp. / ProQuest Investments IV, L.P. - SCHEDULE 13/G-A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
February 1, 2016	SC 13G/A	IMDZ / Immune Design Corp. / Topspin Fund, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L103 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
January 8, 2016	EX-10.1	IMMUNE DESIGN CORP. 2014 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Exhibit IMMUNE DESIGN CORP. 2014 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Immune Design Corp., a Delaware corporation (the ? Company ?), hereby grants restricted stock units relating to the shares of the Company?s common stock, par value $0.001 per share (the ? Common Stock ?), to the Grantee named below. Additional terms and conditions of the grant are set forth on this cover sheet
January 8, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2016 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fil
December 30, 2015	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission F
December 28, 2015	CORRESP	Immune Design ESP CORRESP IMMUNE DESIGN CORP. 1616 Eastlake Ave. E., Suite 310 Seattle, Washington 98102 December 28, 2015 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Riedler Re: Immune Design Corp. Registration Statement on Form S-3 (File No. 333-206324) Request for Acceleration of Effective Date Dear Mr. Riedler: Pursuant to Rule 461 of the General Rules an
November 12, 2015	EX-99.1	Immune Design Reports Third Quarter 2015 Financial Results Company to hold conference call at 1:30 pm Pacific today Immune Design Reports Third Quarter 2015 Financial Results Company to hold conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, November 12, 2015 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the third quarter ended September 30, 2015, which includes advancement of its immuno-oncology programs and a cash position of $120.
November 12, 2015	8-K	Immune Design FORM 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commissi
November 3, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission Fi
August 12, 2015	8-K	Immune Design FORM 8-K (Current Report/Significant Event) ImmuneForm8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (C
August 12, 2015	S-3	Immune Design FORM S-3 IMDZFormS3 Table of Contents As filed with the Securities and Exchange Commission on August 12, 2015 Registration No.
August 12, 2015	EX-99.1	Immune Design Reports Second Quarter 2015 Financial Results Company to hold conference call at 1:30 pm Pacific today exhibit99.1earnings Immune Design Reports Second Quarter 2015 Financial Results Company to hold conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, August 12, 2015 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the second quarter ended June 30, 2015, which included the ann
June 4, 2015	8-K	Immune Design FORM 8-K (Current Report/Significant Event) form8k-filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Com
May 18, 2015	8-K	Immune Design 8-K (Current Report/Significant Event) form8k-meeting UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Co
May 14, 2015	EX-99.1	Immune Design Reports First Quarter 2015 Financial Results Company to hold conference call to review financial results and provide ASCO clinical research update at 8:30 a.m. Eastern today EX-99.1 Exhibit 99.1 Immune Design Reports First Quarter 2015 Financial Results Company to hold conference call to review financial results and provide ASCO clinical research update at 8:30 a.m. Eastern today SEATTLE and SOUTH SAN FRANCISCO, May 14, 2015 Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results for the first quarte
May 14, 2015	8-K	Immune Design FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commissi
May 14, 2015	EX-99.2	Immune Design Announces Positive Data from Three Phase 1 Studies at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Efficacy, Immunogenicity and Safety Data Across Two I-O Approaches to be Presented EX-99.2 Exhibit 99.2 Immune Design Announces Positive Data from Three Phase 1 Studies at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Efficacy, Immunogenicity and Safety Data Across Two I-O Approaches to be Presented SEATTLE and SOUTH SAN FRANCISCO, May 13, 2015 ? Immune Design (Nasdaq: IMDZ) today announced that positive clinical data from three immuno-oncology Phase 1 stu
April 28, 2015	SC 13G/A	IMDZ / Immune Design Corp. / ProQuest Investments IV, L.P. - SCHEDULE 13G/A (AMENDMENT NO. 2) Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
April 23, 2015	EX-99.A	Joint Filing Statement EX-99.A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D/A is filed on behalf of each of us. THE COLUMN GROUP, LP THE COLUMN GROUP GP, LP By: The Column Group GP, LP By: /s/ Peter Svennilson By: /s/ Peter Svennilson Name: Peter Svennilson Name: Peter Svennilson Title: Managing Partner Title: Managing Partner By: /s/ Peter Svennilson
April 23, 2015	SC 13D/A	IMDZ / Immune Design Corp. / COLUMN GROUP L P - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L 103 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name, Address
April 16, 2015	424B4	3,000,000 Shares Immune Design Corp. Common Stock IMDZ 424B4 041615 Filed Pursuant to Rule 424(b)(4) Registration No. 333-203241 PROSPECTUS 3,000,000 Shares Immune Design Corp. Common Stock We are offering 3,000,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol ?IMDZ.? On April 15, 2015, the last reported sale price of our common stock on The NASDAQ Global Market was $27.65 per share. We are a
April 15, 2015	S-1MEF	Immune Design S-1MEF S-1MEF As filed with the Securities and Exchange Commission on April 15, 2015 Registration No.
April 15, 2015	S-1/A	Immune Design S-1/A 2 IMDZ S-1/A 2 As filed with the Securities and Exchange Commission on April 15, 2015 Registration No.
April 15, 2015	DEF 14A	Immune Design DEF 14A imdzproxy2015 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 13, 2015	S-1/A	Immune Design S-1 S-1 3.31.15 Red Table of Contents As filed with the Securities and Exchange Commission on April 13, 2015 Registration No. 333-203241 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 2834 26-2007174 (State or o
April 6, 2015	S-1	Immune Design S-1 S-1 3.31.15 Table of Contents As filed with the Securities and Exchange Commission on April 6, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 2834 26-2007174 (State or other jurisdiction of incorpora
March 31, 2015	S-8	Immune Design S-8 As filed with the Securities and Exchange Commission on March 31, 2015 Registration No.
March 31, 2015	EX-99.1	Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update Imdzearnings991 Immune Design Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update SEATTLE and SOUTH SAN FRANCISCO, March 31, 2015 - Immune Design Corp.
March 31, 2015	8-K	Immune Design 8-K (Current Report/Significant Event) Form8-KEarnings UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation)
March 31, 2015	EX-99.2	Immune Design Announces Positive Topline Data from Three Phase 1 Clinical Trials of Immuno-Oncology Agents Imdzdrelease992 Immune Design Announces Positive Topline Data from Three Phase 1 Clinical Trials of Immuno-Oncology Agents SEATTLE and SOUTH SAN FRANCISCO, March 31, 2015 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on cancer, reported today that analyses of data from three ongoing Phase 1 studies support continued development of its two primary product candidates, CMB305 and G100.
March 19, 2015	8-K	Immune Design 8-K (Current Report/Significant Event) Form 8-K (Coleman) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 19, 2015	EX-99.1	Immune Design Appoints Lewis W. Coleman to Board of Directors EX-99.1 2 exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 Immune Design Appoints Lewis W. Coleman to Board of Directors SEATTLE and SOUTH SAN FRANCISCO, March 19, 2015 - Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Lewis W. Coleman to the company’s board of directors. Mr. Coleman most recently served as Vice-Chairman of DreamWo
March 19, 2015	EX-24	Power of Attorney Power of Attorney The undersigned, Lewis W. Coleman, a member of the Board of Directors of Immune Design Corp., a Delaware corporation (the " Company"), hereby constitutes and appoints Stephen R. Brady, for so long as each such person is an employee of the Company, and Laura Berezin, for so long as she is a partner of a law firm representing the Company, the undersigned's true and lawful attorney-
March 11, 2015	8-K	Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commis
March 11, 2015	EX-99.1	Delaware Court of Chancery Decision Denies Theravectys Motion for Preliminary Injunction EX-99.1 Exhibit 99.1 Delaware Court of Chancery Decision Denies Theravectys Motion for Preliminary Injunction SEATTLE and SOUTH SAN FRANCISCO, March 10, 2015 ? Immune Design Corp. (Nasdaq: IMDZ), a clinical-stage immunotherapy company, today announced that the Delaware Court of Chancery yesterday denied Theravectys SA?s (?TVS?) request for a preliminary injunction that sought to enjoin Immune Desi
March 11, 2015	SC 13G/A	IMDZ / Immune Design Corp. / ProQuest Investments IV, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
March 10, 2015	8-K	Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission F
January 9, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2015 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commi
August 8, 2014	SC 13D	IMDZ / Immune Design Corp. / Alta Partners VIII, L.P. - SCHEDULE 13D - IMMUNE DESIGN - 8-8-14 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(a) Immune Design Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L 103 (CUSIP Number) Larry Randall Alta Partners One Embarcadero Center, Suite 370
August 7, 2014	SC 13D	IMDZ / Immune Design Corp. / Versant Venture Capital III, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* IMMUNE DESIGN CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45252L103 (CUSIP Number) Versant Venture Capi
August 5, 2014	SC 13G	IMDZ / Immune Design Corp. / Topspin Fund, L.P. - FORM SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L103 (CUSIP Number) July 26, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule
August 4, 2014	SC 13D	IMDZ / Immune Design Corp. / COLUMN GROUP L P - SC 13D Activist Investment SC 13D 1 d768521dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Immune Design Corp. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45252L 103 (CUSIP Number) Peter Svennilson The Column Group, LP 1700 Owens Street, Suite 500 San Francisco, CA 94158 (415) 865-2050 (Name, A
August 4, 2014	EX-99.A	Joint Filing Statement EX-99.A 2 d768521dex99a.htm EX-99.A EXHIBIT A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13D is filed on behalf of each of us. THE COLUMN GROUP, LP THE COLUMN GROUP GP, LP By: The Column Group GP, LP By: /s/ Peter Svennilson By: /s/ Peter Svennilson Name: Peter Svennilson Name: Peter Svennilson Title: Managing Partner Title: Managing Partner
August 1, 2014	SC 13G	IMDZ / Immune Design Corp. / Sanofi - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immune Design corp. (Name of Issuer) Common stock, $.001 Par value (Title of Class of Securities) 45252L103 (CUSIP Number) July 29, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
August 1, 2014	EX-24	Power of Attorney Power of Attorney The undersigned, a representative of ProQuest Associates IV, LLC, the general partner of ProQuest Investments IV, L.
July 31, 2014	SC 13G	IMDZ / Immune Design Corp. / ProQuest Investments IV, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No.
July 31, 2014	S-8	IMDZ / Immune Design Corp. S-8 - - S-8 S-8 As filed with the Securities and Exchange Commission on July 31, 2014 Registration No.
July 31, 2014	EX-4.6	Immune Design Corp. 2014 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 4.6 to the Company’s Registration Statement on Form S-8 (File No. 333-197748), as filed with the SEC on July 31, 2014) EX-4.6 Exhibit 4.6 IMMUNE DESIGN CORP. 2014 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 7 3.1. Board. 7 3.2. Committee. 8 3.3. Terms of Awards. 8 3.4. Forfeiture; Recoupment. 9 3.5. No Repricing. 10 3.6. Deferral Arrangement. 10 3.7. No Liability. 10 3.8. Stock Issuance/Book-Entry. 10 4. STOCK SUBJECT TO THE PLAN 11 4.1. Number of Share
July 31, 2014	EX-4.9	Immune Design Corp. 2014 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.9 to the Company’s Registration Statement on Form S-8 (File No. 333-197748), as filed with the SEC on July 31, 2014). EX-4.9 Exhibit 4.9 IMMUNE DESIGN CORP. 2014 EMPLOYEE STOCK PURCHASE PLAN The Board of Directors of the Company has adopted this 2014 Employee Stock Purchase Plan to enable eligible employees of the Company and its Participating Affiliates, through payroll deductions or other cash contributions, to purchase shares of Common Stock. The Plan is for the benefit of the employees of the Company and any
July 31, 2014	EX-24.1	POWER OF ATTORNEY Exhibit 24.1 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned hereby constitutes and appoints, as of the date hereof, Pasquale DeAngelis, his or her true and lawful attorney-in-fact with full power of substitution, resubstitution and revocation, for the undersigned and in the undersigned's name, place and stead, in any and all capacities, including, but not limited to
July 29, 2014	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2014 IMMUNE DESIGN CORP. (Exact name of registrant as specified in its charter) Delaware 001-36561 26-2007174 (state or other jurisdiction of incorporation) (Commission File
July 29, 2014	EX-3.1	Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the SEC on July 29, 2014). EX-3.1 Exhibit 3.1 IMMUNE DESIGN CORP. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Immune Design Corp., a Delaware Corporation (the “Corporation”), hereby certifies as follows. 1. The name of the Corporation is Immune Design Corp. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on February 20, 2008, under the name Vaccsys
July 25, 2014	EX-99.1	IMDZ announces filing of new lawsuit by Theravectys SA Repeats some claims made by TVS in prior lawsuit that it previously voluntarily dismissed EX-99.1 Exhibit 99.1 IMDZ announces filing of new lawsuit by Theravectys SA Repeats some claims made by TVS in prior lawsuit that it previously voluntarily dismissed July 25, 2014, Seattle, WA and South San Francisco, CA – Immune Design (Nasdaq:IMDZ) announced today that the day after it began trading on the Nasdaq Global Market, Theravectys SA (“TVS”) filed a lawsuit against the company repeating

IMDZ / Immune Design Corp. - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)